Caricamento...
Development of Intranasal Levothyroxine Powder Delivery for Hypothyroidism
Background: Hypothyroidism affects 3-5% of the general population with oral levothyroxine (LT4) being the predominant replacement therapy. However, significant proportion of hypothyroid patients are unable to absorb oral replacement leading to therapeutic failure and may require injectable thyroxine...
Salvato in:
| Pubblicato in: | J Endocr Soc |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8089816/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1689 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|